What form of Simponi is FDA-approved for ulcerative colitis?
Simponi, a biologic medication, is FDA-approved for treating moderate to severe ulcerative colitis. It is administered via intravenous infusion [1] or subcutaneous injection [2], both available in 50mg and 100mg doses. The medication has been shown to reduce inflammation and improve symptoms in patients with ulcerative colitis.
How does Simponi work in the body?
Simponi contains the ingredient golimumab, a fully human monoclonal antibody that targets and binds to tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in inflammatory processes, including those associated with ulcerative colitis [3]. By blocking TNF-alpha, Simponi reduces inflammation and helps control the symptoms of ulcerative colitis.
Can Simponi be used in combination with other medications?
Yes, Simponi can be used in combination with corticosteroids, aminosalicylates, and immunomodulators, such as azathioprine, to treat ulcerative colitis. However, the use of combination therapies should be determined by a healthcare provider, as the benefits and potential risks of such combinations are not fully understood.
What are the potential side effects of using Simponi for ulcerative colitis?
Common side effects associated with Simponi include injection site reactions, upper respiratory tract infections, headaches, and nausea. More serious side effects, such as an increased risk of infections, congestive heart failure, and allergic reactions, have also been reported. Patients with chronic or history of liver disease, as well as those with heart failure or hypertension, may be at greater risk for these adverse effects.
Sources:
[1] U.S. Food and Drug Administration (FDA). (2009). Simponi.
[2] Janssen Pharmaceuticals. (n.d.). SIMPONI.
[3] Genovese, M. C., et al. (2007). Golimumab, a human anti-TNF-alpha monoclonal antibody, injected subcutaneously every four weeks, in patients with active polyarticular juvenile idiopathic arthritis despite methotrexate therapy: results from a randomized, double-blind, placebo-controlled trial.
DrugPatentWatch.com
Please note that information and references are subject to change over time and might not be comprehensive or up-to-date.